340B Rebate Model Pilot Clears HRSA Approval, Hospitals Warn of New Burdens
HRSA’s approval of eight manufacturers for its 340B Rebate Model Pilot signals a major pricing shift.
HRSA’s approval of eight manufacturers for its 340B Rebate Model Pilot signals a major pricing shift.
CMS’s payment modernization plan seeks to trim inefficiencies, curb wasteful spending in wound care, and realign value in Medicare reimbursement. Providers brace for tighter margins as policymakers hail a new era of cost discipline.
From October 27, 2025, patients in the Netherlands with spinal metastases or multiple myeloma can access bone cement injections.
ICER pegs an ~$88K benchmark for brensocatib and spotlights evidence gaps shaping NCFB access.
In a transformative week for market access, the CMS and Europe reimbursement pathway expansion delivered several pivotal coverage and pricing decisions reshaping patient access across cardiovascular, hepatic, and oncology therapies. From CMS’s national determinations on breakthrough devices to European HTA approvals in rare disease and cancer, these developments underscore a growing transatlantic alignment between regulators … Read more
Funeral reimbursement could transform U.S. organ donation access and equity.
Evernorth’s pricing model overhaul transforms drug access and reimbursement dynamics.
Successful reimbursement milestone strengthens device adoption and access strategy.
UK braces as drug pricing shifts dramatically in market access landscape.
HAS strengthens stroke management for faster, equitable emergency care access.